NexTel Medical Corp., formerly Exousia Pro, Inc., is a biotechnology company at the intersection of clinical innovation and patient access. The Company specializes in developing proprietary, next-generation exosome-based delivery systems designed to maximize the bioavailability and therapeutic efficacy of bioactive compounds. Through its integrated telehealth division, the Company focuses on streamlining the commercialization pipeline, delivering clinically backed wellness and longevity therapies directly to patients. The Company’s product portfolio includes Maxasome, Maxasome Plus, and Maxasome CBD. Maxasome is a plant-derived exosomes designed to support muscle and bone health with advanced nutrient delivery. Maxasome Plus provides enhanced formulation with additional bioactive compounds for immunity, longevity, and cellular protection. Maxasome CBD delivers through milk-based exosomes for improved absorption and effective stress recovery support.